share_log

Cantor Fitzgerald Maintains Neutral on Amedisys, Raises Price Target to $101

Cantor Fitzgerald Maintains Neutral on Amedisys, Raises Price Target to $101

坎托·菲茨杰拉德对Amedisys保持中立,将目标价上调至101美元
Benzinga ·  2023/09/14 09:11

Cantor Fitzgerald analyst Sarah James maintains Amedisys (NASDAQ:AMED) with a Neutral and raises the price target from $100 to $101.

Cantor Fitzgerald分析师Sarah James维持Amedisys(纳斯达克:AMED)中性,并将目标价从100美元上调至101美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发